Genetron Health to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, announced participation in two virtual investor conferences. Management, including CEO Sizhen Wang and CFO Evan Xu, will conduct a fireside chat on February 16, 2022, at 8:00 am EST, and have investor meetings on February 15-16 at the BTIG MedTech Conference. Additionally, they will hold meetings on February 17-18 at the 11th Annual SVB Leerink Global Healthcare Conference. Genetron specializes in molecular profiling and cancer management solutions.
Positive
- None.
Negative
- None.
News Market Reaction – GTH
In the trading session that priced this news, GTH gained 17.85%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEIJING, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in two upcoming virtual investor conferences.
Sizhen Wang, co-founder and CEO, and Evan Xu, Chief Financial Officer, will participate in a fireside chat on Wednesday, February 16, 2022 at 8:00am EST and conduct investor meetings February 15-16, 2022 at the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
Management will also participate in investor meetings February 17-18, 2022 at the virtual 11th Annual SVB Leerink Global Healthcare Conference.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis, and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit https://ir.genetronhealth.com/.
Investor Relations Contact
US:
Hoki Luk
Head of Investor Relations
Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255
Philip Trip Taylor
Principle | Gilmartin Group
Email: ir@genetronhealth.com
